| DAIICHI PURE CHEMICALS CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122777 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP - The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive/preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor. | 05-17-2012 |
| 20110287460 | METHOD OF LIPID ASSAY AND REAGENT FOR USE THEREIN - A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability. | 11-24-2011 |
| 20110229875 | METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that anon-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. | 09-22-2011 |
| 20110151474 | METHOD OF ESTIMATING THE RISK OF EXPRESSION OF ADVERSE DRUG REACTION CAUSED BY THE ADMINISTRATION OF A COMPOUND, WHICH IS EITHER METABOLIZED PER SE BY UGT1A1 ENZYME OR WHOSE METABOLIC INTERMEDIATE IS METABOLIZED BY THE ENZYME - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. | 06-23-2011 |
| 20110091917 | METHOD OF MEASURING LIPID IN SPECIFIC LIPOPROTEIN - A method of measuring a lipid in a specific lipoprotein characterized by using a polycyclic polyoxyalkylene derivative at least in the step of determining the specificity of the measurement of the target lipid. | 04-21-2011 |
| 20100227309 | METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS - A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholestrols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers. | 09-09-2010 |
| 20100136591 | METHOD OF MEASURING LIPID IN SPECIFIC LIPOPROTEIN - A method of measuring a lipid in a specific lipoprotein characterized by using a polycyclic polyoxyalkylene derivative at least in the step of determining the specificity of the measurement of the target lipid. | 06-03-2010 |
| 20100120160 | Fluorescent Probe - A compound represented by the formula (I) wherein R | 05-13-2010 |
| 20090291461 | METHOD OF SELECTIVELY ASSAYING ADIPONECTIN MULTIMERS - Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody. | 11-26-2009 |
| 20090263910 | METHOD FOR MEASURING HYPOCHLORITE ION - A method for measuring hypochlorite ion, which comprises the steps of: | 10-22-2009 |
| 20090263818 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. | 10-22-2009 |
| 20090215118 | D-AMINOACYLASE - A D-aminoacylase having a high substrate specificity is provided. This D-aminoacylase can produce D-amino acids from N-acetyl-D,L-amino acids conveniently and efficiently at a low cost. | 08-27-2009 |
| 20090215035 | METHOD OF ASSESSING CANCEROUS CONDITIONS AND REAGENT FOR DETECTING GENE PRODUCT TO BE USED IN THE METHOD - It is intended to provide a method of assessing cancerous conditions, which is useful in diagnosing cancer in a therapy or a preventive therapy for cancer diseases or a maintenance therapy therefor, and a reagent for detecting a gene product to be used in the above method. The cancerous conditions of a human-origin specimen is assessed by using, as an indication, the content of a gene product, which shows an increase or a decrease in the expression thereof due to an unusual alternative splicing, from gene products obtained from human PTCH1 gene contained in the human-origin specimen. To measure the content, use is preferably made of, concerning at least one base sequence selected from the group consisting of (a) the base sequences represented by SEQ ID NOS:1 to 4 and (b) base sequences derived from any of the base sequences represented by SEQ ID NOS:1 to 4 by deletion, substitution and/or insertion of one to several bases and having an activity of being hybridized with a chain complementary to the corresponding base sequence selected from the base sequences represented by SEQ ID NOS:1 to 4 under stringent conditions, a probe sequence-specifically binding to the complementary chain of the above-described base sequence or a chemical modification thereof. | 08-27-2009 |
| 20090105464 | PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND DNA - A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, and is thus useful as a medicine for curing circulation diseases, e.g. cardiac edema, nephric edema, hepatic edema, pulmonary edema, hypertension, congestive heart failure, and acute and chronic renal failure. | 04-23-2009 |
| 20090075310 | METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS - A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholesterols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers. | 03-19-2009 |
| 20090029351 | METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells. | 01-29-2009 |
| 20080318238 | METHOD OF DETECTING GENE MUTATION - DNA amplification and hybridization are successively carried out in a reaction system containing primers for the DNA amplification and hybridization probes, followed by detecting the hybrid in the reaction solution by affinity chromatography, wherein at least one of the primers to be used in the DNA amplification is labeled with a first labeling agent so that the amplified DNA will be labeled with the first labeling agent, a hybridization probe is labeled with a second labeling agent and contained in a reaction solution for effecting the DNA amplification, the base sequence of the hybridization probe is designed not to inhibit the DNA amplification, and a hybrid is detected by affinity chromatography with the use of the first and second labeling agents. | 12-25-2008 |
| 20080261314 | FLUORESCENT PROBE FOR ZINC - A compound represented by the following general formula (I) or a salt thereof: | 10-23-2008 |
| 20080241816 | Method for Stabilizing Oxidizable Color Developing Reagent - A method of storing/stabilizing an oxidizable color-assuming reagent, especially a leuco dye; and a stabilized reagent obtained thereby. The method of stabilizing an oxidizable color-assuming reagent comprises storing the oxidizable color-assuming reagent in a solution having a pH of 1 to 5. | 10-02-2008 |
| 20080199847 | Method for Predicting the Metabolism of Drug in Human Liver and Liver Function - The invention provides a method for precisely predicting the metabolism of a drug in human liver and the effect of the drug on liver function. The invention provides a method for predicting a metabolite of a test substance produced in human liver and functions of the liver, wherein the method includes administering a test substance to a nonhuman chimeric animal and a non-chimeric animal of the same species, wherein the chimeric animal intracorporeally carries a population of human-origin hepatocytes having proliferation potential and in which the hepatocyte, population substantially functions as the liver of the chimeric animal, and wherein these animals are protected from the attack by a human complement produced by the hepatocytes; and analyzing and comparing metabolites from the chimeric animal and the non-chimeric animal. | 08-21-2008 |
